Answer
Patients receiving teplizumab (Tzield) should be monitored for signs and symptoms of infection, including viral reactivation, during treatment and for at least 2 months after their last dose.
Sources for this answer
- Tzield 2 mg/2 mL concentrate for solution for infusionSANOFI · emc · SmPC §4.4 Special warnings and precautions for use · Version 3Document updated
Sources checked